The end-to-end pharmacist process for a comprehensive medication review — from gathering a complete list through follow-up — for any patient population
Every comprehensive medication review stands or falls on the quality of the list it starts from. Before any clinical judgment can be applied, the reviewer must assemble a single, reconciled record of everything a patient is actually taking — not just what is on file. Missing a supplement, an as-needed inhaler, or a medication prescribed by a specialist can hide the very problem the review exists to catch.
A patient's pharmacy fill history, the electronic health record, and the patient's own account of what they take rarely agree completely. Each source has blind spots:
• Pharmacy/claims data: captures dispensed prescriptions but misses samples, mail-order fills from other pharmacies, OTC purchases, and supplements bought outside a pharmacy • Prescriber records: reflect what was prescribed, not necessarily what the patient is actually taking, how they are taking it, or whether they stopped on their own • Patient/caregiver interview ("brown bag" review): the patient brings every bottle, blister pack, and container in active use — the single most reliable way to surface unlisted OTC products, supplements, and medications from other prescribers
Reconciling these sources into one list is not a clerical formality — it is the step that determines whether the rest of the review has anything real to work with.
A complete list captures far more than prescription drug names:
• Prescription medications: name, strength, dose, frequency, route, prescriber, and indication if known • Over-the-counter products: analgesics, antihistamines, laxatives, antacids — often taken regularly without being reported as "medication" • Vitamins, minerals, and herbal/dietary supplements: frequently omitted by patients who do not consider them drugs, despite real interaction and duplication potential • As-needed (PRN) medications: including how often they are actually used, not just how they are prescribed • Recently discontinued medications: relevant context for understanding why current therapy looks the way it does
Gaps in any of these categories can hide a medication-related problem that later stages of the review are specifically designed to find — which is why the gathering stage is treated as a distinct, deliberate step rather than an assumed starting point.
An incomplete list undermines the entire subsequent review. Every later stage — appropriateness assessment, interaction screening, prioritization, and follow-up — inherits whatever gaps exist in this first step, which is why thorough source-gathering is treated as foundational rather than a formality.
With a complete list in hand, the reviewer works through each medication individually, asking a consistent set of questions: is there still a valid reason for this medication, is the dose right for this patient now, is it working, and is it safe. This item-by-item pass is where many medication-related problems are first identified.
For each item on the list, the reviewer systematically works through:
• Indication: Is there still a documented or clinically evident reason for this medication? Medications started for a short-term issue sometimes continue indefinitely without anyone revisiting whether they are still needed. • Dose: Is the current dose appropriate for this patient's current weight, age, renal and hepatic function, and other medications? A dose that was correct at initiation may no longer be correct. • Effectiveness: Is the medication achieving its intended clinical goal? A medication that is not working is still exposing the patient to risk without benefit. • Safety: Is the medication causing or contributing to side effects, and is the patient monitored appropriately for known risks of that agent?
Asking these four questions in the same order for every medication keeps the assessment systematic rather than reactive — reducing the chance that a problem is missed simply because attention was focused elsewhere.
Medication-related problems surfaced at this stage typically fall into recognizable categories:
• Therapy without a current indication — the underlying condition has resolved, or the medication was never clearly linked to a documented diagnosis • Suboptimal dosing — too high, too low, or not adjusted for changes in organ function or body weight over time • Adherence concerns — the medication is prescribed but not being taken as directed, whether from cost, side effects, complexity, or misunderstanding • Unaddressed adverse effects — symptoms the patient may not have connected to a medication, or a known risk that has never been monitored • Untreated indications — a condition that would benefit from therapy but has none, sometimes revealed only once the full list is considered together
Each finding at this stage becomes a candidate item for the interaction/duplication screen and the prioritized action plan that follow.
Some medication-related problems are only visible when the list is considered as a whole rather than medication by medication. Drug-drug interactions, therapeutic duplications, and cumulative effects — such as additive sedation or anticholinergic burden — emerge from the relationships between medications, not from any single medication in isolation.
The appropriateness assessment in Stage 2 evaluates each medication against the patient's clinical picture. But some problems only exist in the relationship between two or more medications:
• Drug-drug interactions: one medication alters the absorption, metabolism, or effect of another — sometimes reducing effectiveness, sometimes amplifying toxicity • Therapeutic duplication: two medications from the same class, or with substantially overlapping mechanisms, are prescribed simultaneously — often because they were started by different prescribers unaware of each other • Cumulative effects: no single medication may be flagged individually, yet several together contribute to an additive burden — sedation, fall risk, anticholinergic load, or bleeding risk that only becomes apparent when totaled across the list
This is precisely why the gathering stage (Stage 1) matters so much: a screening step can only catch relationships between medications that are actually on the list.
Systematic screening typically combines automated and clinical judgment:
• Interaction-checking tools flag known pharmacokinetic and pharmacodynamic interactions, ranked by severity, but require clinical interpretation — not every flagged interaction is clinically meaningful for a given patient • Therapeutic class review identifies medications that share a mechanism or indication, surfacing duplications that automated tools may not flag as "interactions" per se • Patient-specific risk factors — renal or hepatic impairment, age, frailty — are layered onto the interaction findings, since the same interaction may be trivial in one patient and significant in another
The output of this stage is a working list of concrete, list-derived problems that feeds directly into prioritization — distinguishing this stage from Stage 2's item-by-item findings, even though both stages contribute to the same overall action plan.
A therapeutic duplication or an additive sedative burden is often invisible when each medication is reviewed on its own — it only becomes visible once the full list is screened together, which is exactly why this is treated as a separate stage rather than folded into the per-medication assessment.
By this point, the review may have surfaced a substantial number of findings — appropriateness concerns from Stage 2 and interaction or duplication findings from Stage 3. Presenting all of them with equal weight would overwhelm the prescriber and the patient alike. This stage organizes findings by clinical significance into an actionable plan.
Findings are triaged rather than presented in the order they happened to be discovered:
• Highest priority: problems with clear potential for serious harm — significant interactions, medications contraindicated for the patient's current condition, or safety issues with immediate consequences • Moderate priority: problems affecting effectiveness or quality of life — suboptimal dosing, unaddressed side effects, duplications without acute danger • Lower priority: optimization opportunities — simplification, cost reduction, or minor adjustments that improve the regimen without addressing an urgent risk
This triage transforms a list of findings into a plan that a prescriber can act on efficiently, and that a patient can actually absorb and follow.
Each item in the action plan pairs a problem with a concrete, actionable recommendation rather than simply noting that something is wrong:
• Instead of "possible interaction flagged" — a specific recommendation: which agent to adjust, discontinue, or monitor, and why • Instead of "dose may be high" — a specific target dose, timeline for reassessment, and any monitoring parameters to track • Instead of "duplication present" — a recommendation on which agent to continue and which to taper or stop
Specific, prioritized recommendations are far more likely to be acted upon than a lengthy list of undifferentiated observations — which is the entire purpose of converting raw findings into a structured action plan before anything is communicated to the prescriber or patient.
A prioritized action plan only produces value once it is communicated clearly and its implementation is confirmed. The final stage closes the loop: recommendations reach the prescriber and the patient in a form each can act on, and a follow-up plan verifies both that changes were made and what effect they had.
The same underlying findings need to be presented differently depending on who is receiving them:
• To the prescriber: a clinically framed summary with specific recommendations, supporting rationale, and relevant patient-specific factors — organized by priority so the most significant items are not buried • To the patient: recommendations translated into plain language, focused on what will actually change in their day-to-day regimen, why the change matters, and what to expect or watch for
Communicating effectively to both audiences — not just documenting recommendations in a chart — is what allows the plan built in Stage 4 to actually be acted upon rather than filed away.
The review is not complete when recommendations are sent — it is complete when their impact has been checked:
• Confirm implementation: were the recommended changes actually made? A recommendation accepted in principle but never enacted delivers no benefit to the patient • Assess effect: for changes that were implemented, did they achieve the intended result — resolved symptom, corrected lab value, simplified regimen — without introducing a new problem? • Set the next checkpoint: follow-up is scheduled at the next contact appropriate to the patient's situation, rather than left open-ended
This follow-up loop is what distinguishes a comprehensive medication review from a one-time audit: it treats the medication list as something that needs periodic re-examination, feeding back into Stage 1 the next time a comprehensive review is warranted.
The workflow is a loop, not a line: confirming that recommendations were implemented — and assessing what effect they had — is what closes Stage 5 back toward Stage 1, since the patient's medication list will need to be gathered fresh at the next comprehensive review.